- About ExoGenis
We unlock the power of biologics - without the burden of injections
- What we
do
ExoGenis is building a controlled biologic delivery platform for regenerative skin actives, positioned between topical skincare and injections
The platform is designed for controlled, repeatable use in clinical settings, enabling a new layer of treatment between major interventions.
our mission
To make precise biologic delivery accessible, predictable and scalable.
our vision
A future where biologic therapies are delivered locally and non-invasively.
.svg)
Biologic-
compatible
.svg)
Non-
injectable
Clinically
focused
.svg)
Scientifically
driven
- our team
Leadership and Scientific advisors
Irina Torres
CEO & Co-founder
EMBA (LBS) - MSc, Strategy, partnerships, IP, regulatory, fundraising
Dr. Elena Tsisanova
CSO, Co-founder
MPharm, MSc, PhD Pharmacology, medical devices, exosomes
Dr. Nina Tsisanova
Scientific advisor
Correction of age-related skin changes, treatment of vascular and pigment pathologies, and therapy for various manifestations of photo- and chronoaging
.svg)
Dr. John Ludlow
Scientific advisor
Tissue engineering, cell therapeutics, regenerative medicine, and GLP/GMP process and assay development for clinical-stage products
- our journey
Milestones
Our technology is validated through rigorous scientific partnerships with leading research institutions.
2025
2026
01
Company founded
ExoGenis was founded to build the missing delivery layer between topical skincare and injections
02
Initial platform development
Defined the regenerative skin delivery platform, product strategy, manufacturing approach and validation roadmap
03
Manufacturing & product validation
Validated manufacturing feasibility, product concept and commercialization strategy through technical testing and manufacturing partners
04
Pilot validation
Pilot the product with selected European dermatology and aesthetic clinics to validate adoption, usability and commercial potential
- Partnerships
Scientific collaborations
Our delivery system is validated through rigorous scientific partnerships with leading research institutions.
Innovationsfonden — non-dilutive funding for technology development
Sono-Tek — coating technology validation for biologic deposition
BioIVT — ex-vivo skin model testing for delivery performance
MedTech Growth — DTU Science Park accelerator program for medical technology companies
Beyond Beta — accelerator support and early-stage validation
Innovationsfonden — non-dilutive funding for technology development
Sono-Tek — coating technology validation for biologic deposition
BioIVT — ex-vivo skin model testing for delivery performance
MedTech Growth — DTU Science Park accelerator program for medical technology companies
Beyond Beta — accelerator support and early-stage validation
Join us in shaping the future
Whether you're a potential partner, investor, or simply curious about our technology, we'd love to hear from you.